{
    "sponsor_name": "",
    "study_acronym": "",
    "tested_imp": "apixaban",
    "comparative_drug": "",
    "study_type": "",
    "interventional_study_phase": "",
    "study_design": "",
    "aim_of_study": "",
    "target_disease": "",
    "type_of_randomization": "",
    "randomization_stratification": [],
    "apixaban_dosing": "",
    "dalteparin_dosing": "",
    "apixaban_supply_form": "",
    "dalteparin_supply_form": "",
    "scheduled_visits": [
        "final follow-up visit at 7 months",
        "primary monitoring period: 6-month treatment period"
    ],
    "primary_efficacy_outcome": "",
    "secondary_efficacy_outcomes": [
        "Assessment of any major cardiovascular event (fatal or non-fatal, including acute myocardial infarction or ischemic stroke)",
        "All-cause death"
    ],
    "primary_safety_outcome": "Incidence of major bleeding, as defined by the International Society on Thrombosis and Haemostasis (ISTH) guidelines. All bleeding criteria will include surgical site bleeding.",
    "secondary_safety_outcomes": [
        "Incidence of clinically relevant non-major bleeding (CRNMB)",
        "Incidence of major bleeding and CRNMB in both treatment arms, with focus on GI and GU cancer patients"
    ],
    "maximum_sample_size_per_arm": 0,
    "recommended_inclusion_criteria": [],
    "recommended_exclusion_criteria": []
}